scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.JHEP.2005.12.015 |
P698 | PubMed publication ID | 16488051 |
P50 | author | Umberto Cillo | Q43274404 |
Giacomo Zanus | Q95630401 | ||
Davide Francesco D'Amico | Q117812114 | ||
P2093 | author name string | Alessandro Vitale | |
Francesco Grigoletto | |||
Fabio Farinati | |||
Daniele Neri | |||
Patrizia Boccagni | |||
Alessio Bridda | |||
Alberto Brolese | |||
Francesco Antonio Ciarleglio | |||
Francesco D'Amico | |||
Nela Srsen | |||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | liver cancer | Q623031 |
Barcelona | Q1492 | ||
P304 | page(s) | 723-731 | |
P577 | publication date | 2006-01-24 | |
P1433 | published in | Journal of Hepatology | Q15724402 |
P1476 | title | Prospective validation of the Barcelona Clinic Liver Cancer staging system | |
P478 | volume | 44 |
Q53233121 | 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. |
Q41601109 | A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression |
Q92424376 | A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma |
Q33966175 | A conceptual proposal for staging ductal cholangiocarcinoma |
Q33916361 | A multidisciplinary approach to the management of hepatocellular carcinoma |
Q84534500 | A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort |
Q89516462 | A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk |
Q53313895 | A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. |
Q39702687 | Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy |
Q36836103 | Advanced hepatocellular carcinoma: which staging systems best predict prognosis? |
Q40707188 | Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. |
Q53379427 | Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. |
Q89927855 | Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma |
Q35833112 | Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center |
Q35780838 | Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival |
Q53220944 | Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. |
Q39692205 | Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? |
Q35594282 | Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging |
Q33805894 | Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective |
Q84388181 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study |
Q33572657 | Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort |
Q36193809 | Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? |
Q36970515 | Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma |
Q26766707 | Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma |
Q92979177 | Challenges of transarterial therapy for hepatocellular carcinoma in patients with chronic kidney disease |
Q37289933 | Clinical implications of basic research in hepatocellular carcinoma |
Q88733788 | Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy |
Q42553272 | Comparative performances of staging systems for early hepatocellular carcinoma |
Q37396794 | Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization |
Q35113002 | Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt |
Q52658496 | Comparison and validation of the prognostic value of preoperative systemic immune cells in hepatocellular carcinoma after curative hepatectomy. |
Q53557508 | Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. |
Q36741673 | Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience |
Q34847211 | Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization |
Q34776673 | Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. |
Q35094309 | Comparison of staging systems of hepatocellular carcinoma |
Q57763504 | Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score |
Q58598133 | Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review |
Q36429818 | Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients |
Q37072518 | Current management of advanced hepatocellular carcinoma |
Q84121761 | Current management of hepatocellular cancer |
Q87604943 | Current management of hepatocellular carcinoma |
Q43093342 | Current management strategy of hepatocellular carcinoma |
Q36360832 | Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma |
Q44195991 | DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma |
Q36634582 | Decreased expression of Sushi Domain Containing 2 correlates to progressive features in patients with hepatocellular carcinoma |
Q37798817 | Developing better treatments in hepatocellular carcinoma |
Q44220846 | Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting |
Q40020398 | Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre |
Q59150373 | Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases |
Q38763789 | Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals |
Q33403106 | Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study |
Q53450730 | Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. |
Q39697040 | Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue |
Q49386865 | Expression of cluster of differentiation 151 prior to and following transcatheter arterial chemoembolization therapy in patients with hepatocellular carcinoma and its association with clinicopathological characteristics |
Q36375463 | FRZB up-regulated in hepatocellular carcinoma bone metastasis |
Q36589471 | Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma |
Q47140323 | Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study |
Q92837846 | Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing |
Q57492763 | HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection |
Q34401855 | HCC surveillance results in earlier HCC detection: results from an Indian cohort |
Q38762094 | HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival. |
Q38460881 | Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis |
Q51550710 | Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. |
Q41315716 | Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System |
Q36487795 | Hepatocellular Carcinoma Related to Schistosoma mansoni Infection: Case Series and Literature Review |
Q35818322 | Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia: Case Report and Literature Review. |
Q26767217 | Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective |
Q55312644 | Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. |
Q48268747 | Hepatocellular Carcinoma: Surgical Management and Evolving Therapies |
Q26783881 | Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols |
Q37863539 | Hepatocellular carcinoma: MR staging and therapeutic decisions. |
Q54988303 | High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma. |
Q38984450 | In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? |
Q48034232 | Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma |
Q36327007 | Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101 |
Q51918787 | Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. |
Q64068788 | Is there a sex difference in postoperative prognosis of hepatocellular carcinoma? |
Q50890846 | Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. |
Q64984085 | Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. |
Q26748756 | Liver resection for intermediate hepatocellular carcinoma |
Q47601267 | Liver resection: a regional hospital experience |
Q24658550 | Liver transplantation for hepatocellular carcinoma beyond the Milan criteria |
Q50100582 | Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma |
Q34662021 | Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience |
Q58563301 | Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection |
Q38615117 | Major Liver Resection for Large and Locally Advanced Hepatocellular Carcinoma |
Q28258769 | Management of HCC |
Q35771842 | Management of Hepatocellular Carcinoma: Current Status and Future Directions |
Q24186856 | Management of people with early or very early stage hepatocellular carcinoma: a network meta-analysis |
Q34681207 | Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. |
Q24186892 | Management of people with intermediate-stage hepatocellular carcinoma: a network meta-analysis |
Q38747707 | Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. |
Q42373841 | Mesoporous composite nanoparticles for dual-modality ultrasound/magnetic resonance imaging and synergistic chemo-/thermotherapy against deep tumors |
Q34017735 | Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies |
Q38935553 | Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration |
Q37384682 | Multimodal approaches to the treatment of hepatocellular carcinoma |
Q35469188 | Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival |
Q38904263 | New concepts in embolotherapy of HCC. |
Q48328889 | New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. |
Q49901774 | Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma |
Q48741048 | Novel treatment strategy for advanced hepatocellular carcinoma: combination of conventional transcatheter arterial chemoembolization and modified method with portal vein occlusion for cases with arterioportal shunt: a preliminary study |
Q90678432 | Ontology-Based Approach for Liver Cancer Diagnosis and Treatment |
Q36069902 | Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study |
Q90288434 | Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification |
Q35792080 | Perineural invasion: a potential reason of hepatocellular carcinoma bone metastasis |
Q42148721 | Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. |
Q49637785 | Prediction of long-term survival rates in patients undergoing curative resection for solitary hepatocellular carcinoma |
Q42129377 | Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma |
Q30432108 | Pretreatment assessment of hepatocellular carcinoma: expert consensus statement |
Q34061430 | Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems |
Q58283723 | Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages |
Q35114970 | Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. |
Q36194925 | Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma |
Q38216004 | Prognostic factors for hepatocellular carcinoma recurrence |
Q37263149 | Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies |
Q37235913 | Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis |
Q92308889 | Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma |
Q51731281 | Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. |
Q45283698 | Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials |
Q37012028 | Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience |
Q36009475 | Reduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer. |
Q37338042 | Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma |
Q60936594 | Risk factors for liver Cancer in HIV endemic areas of Western Kenya |
Q83186403 | Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma |
Q35738710 | Role functioning is associated with survival in patients with hepatocellular carcinoma |
Q26851627 | Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma |
Q53622404 | Safety and long-term outcomes of anatomic left hepatic trisectionectomy for intermediate and advanced hepatocellular carcinoma. |
Q37169718 | Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score |
Q36163425 | Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma |
Q91638397 | Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study |
Q33773415 | Staging of biliary tract and primary liver tumors |
Q38408876 | Staging systems for hepatocellular carcinoma: Current status and future perspectives |
Q38207014 | Staging systems of hepatocellular carcinoma: a review of literature |
Q38661482 | State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma |
Q38948642 | Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. |
Q58576483 | Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status |
Q58576456 | Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis |
Q83609995 | Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging |
Q64885102 | Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification? |
Q36192647 | Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. |
Q50535030 | Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. |
Q55505579 | Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. |
Q38201654 | TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications |
Q37606028 | The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy |
Q38217657 | The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. |
Q33365826 | The impact of new data in the treatment of advanced hepatocellular carcinoma |
Q35234037 | The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus |
Q40136684 | Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma |
Q41985384 | Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India |
Q26784223 | Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system |
Q59135179 | Transcatheter arterial chemoembolization monotherapy vs combined transcatheter arterial chemoembolization–percutaneous microwave coagulation therapy for massive hepatocellular carcinoma (≥10 cm) |
Q38549768 | Treatment of Liver Cancer |
Q30637327 | Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital |
Q34571160 | Updates in the management of hepatocellular carcinoma |
Q89767591 | Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma |
Q26743666 | Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments |
Q36001102 | Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study |
Q53164616 | Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis. |
Q51828236 | Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. |
Q47843414 | When to perform hepatic resection for intermediate-stage hepatocellular carcinoma |
Q36326015 | Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma |
Search more.